Aurinia Pharmaceuticals
AUPH
170 hedge funds and large institutions have $683M invested in Aurinia Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 55 increasing their positions, 47 reducing their positions, and 20 closing their positions.
125% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 20
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
17% more funds holding
Funds holding: 145 → 170 (+25)
17% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 47
4.77% less ownership
Funds ownership: 46.02% → 41.24% (-4.8%)
15% less capital invested
Capital invested by funds: $806M → $683M (-$123M)
24% less call options, than puts
Call options by funds: $23.9M | Put options by funds: $31.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$51.5M |
| 2 |
O
OrbiMed
New York
|
+$19.1M |
| 3 |
DCM
DG Capital Management
New York
|
+$8.58M |
| 4 |
BC
Blackcrane Capital
Bellevue,
Washington
|
+$7.3M |
| 5 |
Fidelity International
Hamilton,
Bermuda
|
+$6.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$86.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$26.5M |
| 3 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$22.7M |
| 4 |
ABG
Ally Bridge Group
New York
|
-$11.9M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$10.6M |
AUPH Hedge Fund Activity: Q1 2021 in Review
170 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q1 2021, worth a combined $683M — down 15% from $806M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new AUPH positions and 20 closed out — a net gain of 25 holders — while 55 added to existing stakes and 47 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $51.5M. The largest seller was HealthCor Management, cutting an estimated $86.9M.
- 170 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q1 2021, up from 145 in Q4 2020.
- Funds reported $683M of Aurinia Pharmaceuticals stock for Q1 2021, down 15% quarter-over-quarter.
- 45 funds opened new Aurinia Pharmaceuticals positions in Q1 2021 and 20 closed out, a net change of +25 holders.
- The largest Aurinia Pharmaceuticals buyer in Q1 2021 was Fidelity Investments, an estimated $51.5M added.
- The largest Aurinia Pharmaceuticals seller in Q1 2021 was HealthCor Management, an estimated $86.9M sold.
Based on aggregated 13F filings for Q1 2021.